Chronic obstructive pulmonary disease in China: a nationwide prevalence study

The Lancet Respiratory Medicine

Volumn 6, Issue 6, 2018, Pages 421-430

  Fang, Liwen ^a   Gao, Pei ^b   Bao, Heling ^a   Tang, Xun ^b   Wang, Baohua ^a   Feng, Yajing ^a   Cong, Shu ^a   Juan, Juan ^b   Fan, Jing ^a   Lu, Ke ^b   Wang, Ning ^a   Hu, Yonghua ^b   Wang, Linhong ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CHINA; CHINESE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL OUTCOME; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; GEOGRAPHY; HEALTH SURVEY; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; AGED; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SEX RATIO; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CHINA; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SMOKING;

EID: 85045121640     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(18)30103-6     Document Type: Article

References (34)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2017 report). http://goldcopd.org/download/326/wms-GOLD-2017-FINAL.pdf (accessed March 19, 2018).
2. Adeloye, D, Chua, S, Lee, C, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health, 5, 2015, 020415.
3. Dwyer-Lindgren, L, Bertozzi-Villa, A, Stubbs, RW, et al. Trends and patterns of differences in chronic respiratory disease mortality among US counties, 1980–2014. JAMA 318 (2017), 1136–1149.
4. Bousquet, J, Khaltaev, NG, Cruz, AA, et al. Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach. http://www.who.int/gard/publications/GARD%20Book%202007.pdf?ua=1, 2007 (accessed March 5, 2018).
5. GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390 (2017), 1151–1210.
6. World Health Organization. Chronic respiratory diseases: burden of COPD. http://www.who.int/respiratory/copd/burden/en/index.html (accessed March 5, 2018).
7. Zhong, N, Wang, C, Yao, W, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med 176 (2007), 753–760.
8. Bao, H, Fang, L, Wang, L, Prevalence of chronic obstructive pulmonary disease among community population aged ≥40 in China: a meta-analysis on studies published between 1990 and 2014. Zhonghua Liu Xing Bing Xue Za Zhi 37 (2016), 119–124 (in Chinese).
9. Qiu, J, Zhang, YN, Chen, J, et al. Prevalence of chronic obstructive pulmonary disease in Ningxia Hui Autonomous Region of China. Zhonghua Jie He He Hu Xi Za Zhi 36 (2013), 265–268 (in Chinese).
10. Smith, M, Li, L, Augustyn, M, et al. Prevalence and correlates of airflow obstruction in approximately 317 000 never-smokers in China. Eur Respir J 44 (2014), 66–77.
11. Wang, YC, Lin, JM, Li, CY, Lee, LT, Guo, YL, Sung, FC, Prevalence and risks of chronic airway obstruction: a population cohort study in Taiwan. Chest 131 (2007), 705–710.
12. Kurmi, OP, Li, L, Smith, M, et al. Regional variations in the prevalence and misdiagnosis of air flow obstruction in China: baseline results from a prospective cohort of the China Kadoorie Biobank (CKB). BMJ Open Respir Res, 1, 2014, e000025.
13. Liu, S, Wu, X, Lopez, AD, et al. An integrated national mortality surveillance system for death registration and mortality surveillance, China. Bull World Health Organ 94 (2016), 46–57.
14. Wang, L, Gao, P, Zhang, M, et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA 317 (2017), 2515–2523.
15. American Association for Public Opinion Research (AAPOR). Standard definitions: final dispositions of case codes and outcome rates for surveys. http://www.aapor.org/AAPOR_Main/media/publications/Standard-Definitions20169theditionfinal.pdf, 2016 (accessed March 5, 2018).
16. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 152 (1995), 1107–1136.
17. Buist, AS, McBurnie, MA, Vollmer, WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 370 (2007), 741–750.
18. Menezes, AMB, Perez-Padilla, R, Jardim, JRB, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 366 (2005), 1875–1881.
19. Jian, W, Gao, Y, Hao, C, et al. Reference values for spirometry in Chinese aged 4–80 years. J Thorac Dis 9 (2017), 4538–4549.
20. Benjamin, D, Berger, J, Johannesson, M, et al. Redefine statistical significance. Nat Hum Behav 2 (2018), 6–10.
21. von Elm, E, Altman, DG, Egger, M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370 (2007), 1453–1457.
22. Srivastava, K, Thakur, D, Sharma, S, Punekar, YS, Systematic review of economic burden in symptomatic chronic obstructive pulmonary disease (COPD) patients. Value Health 17 (2014), A173–A174 (abstr PRS26).
23. Ko, FWS, Wong, GWK, Drug treatment for early-stage COPD. N Engl J Med 377 (2017), 988–989.
24. Tilert, T, Dillon, C, Paulose-Ram, R, Hnizdo, E, Doney, B, Estimating the US prevalence of chronic obstructive pulmonary disease using pre- and post-bronchodilator spirometry: the National Health and Nutrition Examination Survey (NHANES) 2007–2010. Respir Res, 14, 2013, 103.
25. Fukahori, S, Matsuse, H, Takamura, N, et al. Prevalence of chronic obstructive pulmonary diseases in general clinics in terms of FEV1/FVC. Int J Clin Pract 63 (2009), 269–274.
26. Hong, JY, Jung, JY, Lee, MG, et al. Changes in the prevalence of COPD in Korea between 2001 and 2011 in the KNHANES data. Respir Med 125 (2017), 12–18.
27. Yin, P, Jiang, CQ, Cheng, KK, et al. Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort Study. Lancet 370 (2007), 751–757.
28. US Preventive Services Task Force (USPSTF). Screening for chronic obstructive pulmonary disease: US Preventive Services Task Force recommendation statement. JAMA 315 (2016), 1372–1377.
29. Press, VG, Cifu, AS, White, SR, Screening for chronic obstructive pulmonary disease. JAMA 318 (2017), 1702–1703.
30. Zhou, Y, Zhong, NS, Li, X, et al. Tiotropium in early-stage chronic obstructive pulmonary disease. N Engl J Med 377 (2017), 923–935.
31. Tian, J, Zhou, Y, Cui, J, et al. Peak expiratory flow as a screening tool to detect airflow obstruction in a primary health care setting. Int J Tuberc Lung Dis 16 (2012), 674–680.
32. Guan, W-J, Ran, P-X, Zhong, N-S, Prevention and management of COPD in China: successes and major challenges. Lancet Respir Med 4 (2016), 428–430.
33. Zhou, Y, Hu, G, Wang, D, et al. Community based integrated intervention for prevention and management of chronic obstructive pulmonary disease (COPD) in Guangdong, China: cluster randomised controlled trial. BMJ, 341, 2010, c6387.
34. Postma, DS, Rabe, KF, The asthma-COPD overlap syndrome. N Engl J Med 373 (2015), 1241–1249.